to create products from the medicinal herb Artemisia annua and Artemisia afra with markets in developing countries and elsewhere to capitalize on:
• the standardization of plant cultivation via AmeriCert International/ cGAP certification
• quality of assurance in manufacturing via ASI/cGMP certification
• the global need to address ‘natural product’ efficacy against tropical maladies. *
To propagate, harvest and manufacture FDA/GRAS bio-medicinal herbal products of Artemisia annua L. and Artemisia afra, centralized at our existing horticultural nursery and processing facility in South Florida. In addition, our IMP herbs grown, harvested and milled by Atelier Temenos at our Homestead, FL site have been approved and listed on the NOP Organic Input Review Registry.
Atelier Temenos appreciates working along with the ongoing Artemisia annua research of Professor Pamela Weather’s lab at Worcester Polytechnic Institute (WPI). Prof Weathers is a Fellow of AAAS and SIVB, who is an internationally recognized expert whose work with Artemisia annua and artemisinin research encompasses over 25 years and going strong!
Atelier Temenos alsorecently has established testing Artemisia annua and Artemisia afra analytical methods via Associate Professor Diego Salazar Amoretti of the Plant Chemical Ecology Lab, at Florida International University (FIU). Christopher Baraloto, Director of the International Center for Tropical Botany at FIU, will also be assisting with developing further cultivation protocols for our Artemisia annua and Artemisia afra cultivars.
Atelier Temenos, as well, has been collaborating with La Maison De l’Artemisia, Paris, France, as a ‘seed bank’, developing Artemisia annua and Artemisia afra cultivars that are most suited for the tropics, to assist their valuable international work in over 23 African countries. maison-artemisia.org
The quality control and standardization for propagation, harvesting and manufacturing via authorized certifications of a 100% Artemisia based product. There is no Artemisia annua or Artemisia afra commercial products that meet those criteria globally.
*An estimated 219 million people suffered from malaria in 2017 and 435,000 died. More than 90 % of the deaths were in Africa and over 60% were among children under 5-year-old. These deaths are predominantly in developing countries, located in tropical climates…. however, with the rise in global warming, there are predictions that even more humans will become venerable to malaria outbreaks.
The active ingredient artemisinin synthesized from the Artemisia annua and used as artemisinin combination therapy (ACT), is the current best therapeutic for treating malaria. But it is expensive to produce, is in short supply in areas hit hardest by the disease, and the malaria parasite is showing signs of resistance to ACT, particularly in Southeast Asia.
Today, it has been proven that dried leaves of the Artemisia annua plant delivers 40 times more artemisinin in the blood than does the drug based on the chemical extract of the plant, that it is more effective in knocking out the parasite and reduces the level of parasite infection. It constitutes a robust natural combination therapy, one whose benefits far surpass those of ACT and other combination drugs.
Artemisia annua is also known to be efficacious against a range of other disease, including other tropical maladies. Recent Worcester Polytechnic Institute research includes positive tuberculosis efficacy and a John Hopkins Bloomberg School of Public Heath clinical trial included Artemisia annua as one of their effective ‘ethnobotanical medicines’ against Lyme disease.
*The below table lists areas where artemisinin many be beneficial based upon current data available.
To meet federal regulations in order to enter the pharmaceutical drug market. The list of targeted indications is shown below in Figure 1. Market analysis for both short and long term will include both the United States and Canada.
Figure 1: This table lists areas where artemisinin may be beneficial based on current data available.